|
Status
|
Topic selection
|
|
Technology type
|
Medicine
|
|
Decision
|
Not selected
|
|
Reason for decision
|
Not eligible for Health Technology Evaluation guidance
|
|
Further information
|
This topic was presented to the Topic Selection Oversight Panel (TSOP) on March 2022 where it was agreed that a Technology Appraisal (TA) was not appropriate.
Dulaglutide has been routed to NICE Centre for Guidelines where the topic will be considered for potential inclusion within the next review of NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management. Please note that timelines for a potential review of NG18: Diabetes (type 1 and type 2) in children and young people are to be confirmed. Please contact: surveillance@nice.org.uk for further information
|
| ID number |
10660
|
Project Team
| Project lead |
danielle.lees@nice.org.uk |
Email enquiries
For further information on how we select topics for development, please see our page about topic selection